285 related articles for article (PubMed ID: 28072764)
21. Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.
Triguero A; Xicoy B; Zamora L; Jiménez MJ; García O; Calabuig M; Díaz-Beyá M; Arzuaga J; Ramos F; Medina A; Bernal T; Talarn C; Coll R; Collado R; Chen TH; Borrás J; Brunet S; Marchante I; Marco V; López-Cadenas F; Calbacho M; Simiele A; Cortés M; Cedena MT; Pedreño M; Aguilar C; Pedró C; Fernández M; Stoica C; Ribera JM; Sanz G
Leuk Res; 2022 May; 116():106836. PubMed ID: 35405632
[TBL] [Abstract][Full Text] [Related]
22. Treatment advances for pediatric and adult onset neoplasms with monocytosis.
McCullough KB; Kuhn AK; Patnaik MM
Curr Hematol Malig Rep; 2021 Jun; 16(3):256-266. PubMed ID: 33728588
[TBL] [Abstract][Full Text] [Related]
23. 5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes.
Gawlitza AL; Speith J; Rinke J; Sajzew R; Müller EK; Schäfer V; Hochhaus A; Ernst T
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2835-2843. PubMed ID: 31506740
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of action of trabectedin in desmoplastic small round cell tumor cells.
Uboldi S; Craparotta I; Colella G; Ronchetti E; Beltrame L; Vicario S; Marchini S; Panini N; Dagrada G; Bozzi F; Pilotti S; Galmarini CM; D'Incalci M; Gatta R
BMC Cancer; 2017 Feb; 17(1):107. PubMed ID: 28166781
[TBL] [Abstract][Full Text] [Related]
25. Integrated molecular profiling of juvenile myelomonocytic leukemia.
Murakami N; Okuno Y; Yoshida K; Shiraishi Y; Nagae G; Suzuki K; Narita A; Sakaguchi H; Kawashima N; Wang X; Xu Y; Chiba K; Tanaka H; Hama A; Sanada M; Ito M; Hirayama M; Watanabe A; Ueno T; Kojima S; Aburatani H; Mano H; Miyano S; Ogawa S; Takahashi Y; Muramatsu H
Blood; 2018 Apr; 131(14):1576-1586. PubMed ID: 29437595
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia.
Loh ML
Br J Haematol; 2011 Mar; 152(6):677-87. PubMed ID: 21623760
[TBL] [Abstract][Full Text] [Related]
27. Trabectedin for the treatment of breast cancer.
D'Incalci M; Zambelli A
Expert Opin Investig Drugs; 2016; 25(1):105-15. PubMed ID: 26592307
[TBL] [Abstract][Full Text] [Related]
28. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
29. Trabectedin's contribution to the treatment of sarcomas.
Blay JY
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):3-9. PubMed ID: 23638729
[TBL] [Abstract][Full Text] [Related]
30. Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response.
García MJ; Saucedo-Cuevas LP; Muñoz-Repeto I; Fernández V; Robles MJ; Domingo S; Palacios J; Aracil M; Nieto A; Tercero JC; Benítez J
Mol Cancer Ther; 2013 Apr; 12(4):530-41. PubMed ID: 23364677
[TBL] [Abstract][Full Text] [Related]
31. [Juvenile myelomonocytic leukemia: A three-case series].
Ghariani I; Jmili-Braham N; Regaieg H; Achour B; Ben Youssef Y; Sendi H; Bakir L; Kortas M
Arch Pediatr; 2016 Dec; 23(12):1264-1269. PubMed ID: 27789175
[TBL] [Abstract][Full Text] [Related]
32. [Juvenile myelomonocytic leukemias].
Lachenaud J; Strullu M; Baruchel A; Cavé H
Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
[TBL] [Abstract][Full Text] [Related]
33. MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Wei Y; Zheng H; Lockyer PP; Darbaniyan F; Li Z; Kanagal-Shamanna R; Soltysiak KA; Yang H; Ganan-Gomez I; Montalban-Bravo G; Chien KS; Do KA; Daver N; Garcia-Manero G
Leuk Lymphoma; 2022 Dec; 63(13):3154-3164. PubMed ID: 36059252
[TBL] [Abstract][Full Text] [Related]
34. Role of macrophage targeting in the antitumor activity of trabectedin.
Germano G; Frapolli R; Belgiovine C; Anselmo A; Pesce S; Liguori M; Erba E; Uboldi S; Zucchetti M; Pasqualini F; Nebuloni M; van Rooijen N; Mortarini R; Beltrame L; Marchini S; Fuso Nerini I; Sanfilippo R; Casali PG; Pilotti S; Galmarini CM; Anichini A; Mantovani A; D'Incalci M; Allavena P
Cancer Cell; 2013 Feb; 23(2):249-62. PubMed ID: 23410977
[TBL] [Abstract][Full Text] [Related]
35. [Progress in research of the pathogenesis of childhood MDS/MPN].
Yoshida K
Rinsho Ketsueki; 2018; 59(10):2284-2289. PubMed ID: 30305537
[TBL] [Abstract][Full Text] [Related]
36. LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents.
Chien KS; Class CA; Montalban-Bravo G; Wei Y; Sasaki K; Naqvi K; Ganan-Gomez I; Yang H; Soltysiak KA; Kanagal-Shamanna R; Do KA; Kantarjian HM; Garcia-Manero G
Leuk Lymphoma; 2020 Jun; 61(6):1493-1499. PubMed ID: 32036728
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of children with myelodysplastic syndrome: importance of extramedullary disease as a presenting symptom.
Hiçsönmez G; Cetin M; Yenicesu I; Olcay L; Koç A; Aktaş D; Tunçbilek E; Tuncer M
Leuk Lymphoma; 2001 Aug; 42(4):665-74. PubMed ID: 11697496
[TBL] [Abstract][Full Text] [Related]
38. RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia cells in vitro.
Ohtsuka Y; Manabe A; Kawasaki H; Hasegawa D; Zaike Y; Watanabe S; Tanizawa T; Nakahata T; Tsuji K
Blood; 2005 Nov; 106(9):3134-41. PubMed ID: 16046524
[TBL] [Abstract][Full Text] [Related]
39. Expression of the Evi-1 gene in haemopoietic cells of children with juvenile myelomonocytic leukaemia and normal donors.
Gerhardt TM; Schmahl GE; Flotho C; Rath AV; Niemeyer CM
Br J Haematol; 1997 Dec; 99(4):882-7. PubMed ID: 9432037
[TBL] [Abstract][Full Text] [Related]
40. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
